三氧化二砷联合顺铂治疗恶性胸腔积液的临床研究  

A Clinical Study on Arsenic Trioxide Combined with Cisplatin in the Treatment of Malignant Pleural Effusion

作　　者：杨雪梅[1] 陈远航[1] 曾守群[1] 戴刚毅[1] 曾贵林[1] 孟又胜[1] 

机构地区：[1]成都市第五人民医院肿瘤科,成都611300

出　　处：《华西医学》2013年第5期707-709,共3页West China Medical Journal

基　　金：成都市温江区科技局课题(WJKJXM2011-10)~~

摘　　要：目的观察三氧化二砷联合顺铂腔内注射治疗恶性胸腔积液的疗效和毒副反应。方法 2011年9月-2012年9月,将恶性胸腔积液患者60例,随机分为治疗组和对照组,每组各30例。在胸腔积液充分引流后,治疗组胸腔内注射三氧化二砷20 mg联合顺铂60 mg;对照组只给予胸腔灌注顺铂60 mg,胸腔灌注化学疗法药物两组均1次/周,共3次。观察疗效及不良反应。结果治疗组和对照组的有效率分别为93.3%和56.7%(P<0.05)。治疗组和对照组的一般状况改善率分别为70.0%和40.0%(P<0.05)。两组的不良反应相近。结论三氧化二砷联合顺铂腔内注射治疗恶性胸腔积液具有协同增效作用,不良反应小。Objective To evaluate the efficacy and side-effects of arsenic trioxide combined with cisplatin in treating malignant pleural effusion by injecting it into the pleural cavity. Methods Sixty patients with malignant hydrothorax diagnosed between September 2011 and September 2012 were randomized into two groups. After the accumulation of pleural fluid had adequately drained, 30 patients were randomized to treatment group, receiving arsenic trioxide 20 mg plus cisplatin 60 mg once a week for 3 times, and the other 30 patients were randomized to control group, receiving cisplatin 60 mg once a week for 3 times. Then the efficacy and toxicity were evaluated. Results The overall response rates in the treatment group and in the control group were 93.3% and 56.7% （P 〈 0.05）, respectively. The total modification rates in the treatment group and the control group were 70% and 40% （P 〈 0.05）, respectively. There was no difference in toxicity between the two groups. Conclusions Pleural cavity infusion of arsenic trioxide combined with cisplatin has combined synergies. The treatment is well tolerated with little adverse toxic reaction.

关 键 词：三氧化二砷 顺铂 胸腔内灌注 恶性胸腔积液 

分 类 号：R730.5[医药卫生—肿瘤]